DeFilipp, Zachariah and Couriel, Daniel R. and Lazaryan, Aleksandr and Bhatt, Vijaya Raj and Buxbaum, Nataliya P. and Alousi, Amin M. and Olivieri, Attilio and Pulanic, Drazen and Halter, Joerg P. and Henderson, Lori A. and Zeiser, Robert and Gooley, Ted A. and MacDonald, Kelli P. A. and Wolff, Daniel and Schultz, Kirk R. and Paczesny, Sophie and Inamoto, Yoshihiro and Cutler, Corey S. and Kitko, Carrie L. and Pidala, Joseph A. and Lee, Stephanie J. and Socie, Gerard and Sarantopoulos, Stefanie and Pavletic, Steven Z. and Martin, Paul J. and Blazar, Bruce R. and Greinix, Hildegard T. (2021) National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2020 Treatment of Chronic GVHD Report. TRANSPLANTATION AND CELLULAR THERAPY, 27 (9). pp. 729-737. ISSN 2666-6375, 2666-6367
Full text not available from this repository. (Request a copy)Abstract
Positive results from recent clinical trials have significantly expanded current therapeutic options for patients with chronic graft-versus-host disease (GVHD). However, new insights into the associations between clinical characteristics of chronic GVHD, pathophysiologic mechanisms of disease, and the clinical and biological effects of novel therapeutic agents are required to allow for a more individualized approach to treatment. The current report is focused on setting research priorities and direction in the treatment of chronic GVHD. Detailed correlative scientific studies should be conducted in the context of clinical trials to evaluate associations between clinical outcomes and the biological effect of systemic therapeutics. For patients who require systemic therapy but not urgent initiation of glucocorticoids, clinical trials for initial systemic treatment of chronic GVHD should investigate novel agents as monotherapy without concurrently starting glucocorticoids, to avoid confounding biological, pathological, and clinical assessments. Clinical trials for treatment-refractory disease should specifically target patients with incomplete or suboptimal responses to most recent therapy who are early in their disease course. Close collaboration between academic medical centers, medical societies, and industry is needed to support an individualized, biology-based strategic approach to chronic GVHD therapy. (C) 2021 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | FAILURE-FREE SURVIVAL; SYSTEMIC TREATMENT; RANDOMIZED-TRIAL; THERAPY; PREDNISONE; DIAGNOSIS; CYCLOSPORINE; THALIDOMIDE; MANAGEMENT; IBRUTINIB; Chronic graft-versus-host disease; Allogeneic hematopoietic cell transplantation; Consensus Initial therapy; Treatment refractory |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Innere Medizin III (Hämatologie und Internistische Onkologie) |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 04 Oct 2022 06:27 |
| Last Modified: | 04 Oct 2022 06:27 |
| URI: | https://pred.uni-regensburg.de/id/eprint/48173 |
Actions (login required)
 |
View Item |
